JP2011037906A - Arachidonic acid metabolism inhibitor - Google Patents
Arachidonic acid metabolism inhibitor Download PDFInfo
- Publication number
- JP2011037906A JP2011037906A JP2010264285A JP2010264285A JP2011037906A JP 2011037906 A JP2011037906 A JP 2011037906A JP 2010264285 A JP2010264285 A JP 2010264285A JP 2010264285 A JP2010264285 A JP 2010264285A JP 2011037906 A JP2011037906 A JP 2011037906A
- Authority
- JP
- Japan
- Prior art keywords
- arachidonic acid
- acid metabolism
- metabolism inhibitor
- inhibitor
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、アラキドン酸代謝抑制剤に関する。さらには、アラキドン酸の代謝を抑制することによる血流改善剤、抗血栓剤、抗炎症剤などに関する。 The present invention relates to an arachidonic acid metabolism inhibitor. Furthermore, the present invention relates to a blood flow improving agent, an antithrombotic agent, an anti-inflammatory agent and the like by suppressing the metabolism of arachidonic acid.
各種プロスタグランジン類やトロンボキサンなどは、アラキドン酸を出発物質として生合成されることが知られている。これらアラキドン酸代謝産物は、生体内の各種調節機構に関与していることが知られている一方、炎症や血栓の生成にも深く関与していることも知られている。また、近年、一般に血液の流動性やアレルギー性のものを含む各種炎症の改善などに対する関心が高まっており、このアラキドン酸の代謝経路を制御することによって、様々な症状を緩和する方法が注目されている。たとえば、キノリルメトキシフェニル酢酸やその誘導体によるアラキドン酸代謝の抑制（特許文献１）、桑白皮、甘草の抽出物またはその成分によるアラキドン酸代謝異常の治療（特許文献２）、モルギンまたはその誘導体によるアラキドン酸代謝を阻害する方法（特許文献３）、カンキツ果皮抽出物によりアラキドン酸代謝酵素を阻害する方法（特許文献４）などが提案されている。
また、カプサイシンやトウガラシ抽出物が血流促進効果を有することが知られているが、これらは刺激が強いため投与方法や投与量に制限があるなど使用方法や用途が限られている。
Various prostaglandins and thromboxanes are known to be biosynthesized using arachidonic acid as a starting material. While these arachidonic acid metabolites are known to be involved in various regulatory mechanisms in the living body, it is also known to be deeply involved in inflammation and thrombus generation. In recent years, there has been an increasing interest in improving various inflammations, including blood fluidity and allergic properties, and attention has been focused on methods for alleviating various symptoms by controlling the metabolic pathway of arachidonic acid. ing. For example, inhibition of arachidonic acid metabolism by quinolylmethoxyphenylacetic acid and its derivatives (Patent Document 1), treatment of abnormal arachidonic acid metabolism by mulberry bark, licorice extract or its components (Patent Document 2), morgine or its derivatives There are proposed a method for inhibiting arachidonic acid metabolism (Patent Document 3), a method for inhibiting arachidonic acid-metabolizing enzyme with citrus peel extract (Patent Document 4), and the like.
In addition, capsaicin and pepper extract are known to have a blood flow promoting effect, but their use is limited because of their strong irritation, such as limited administration methods and doses.
本発明は、アラキドン酸代謝が原因で引き起こされる様々な生体への悪影響の症状を軽減し、もしくは予防することができる、新規なアラキドン酸代謝抑制剤を提供すること、特に、より簡便に入手できるとともに、大量生産が容易に実現可能なアラキドン酸代謝抑制剤を提供することを目的とする。 The present invention provides a novel arachidonic acid metabolism inhibitor that can reduce or prevent various symptoms of adverse effects on the living body caused by arachidonic acid metabolism, and is particularly easily available. Another object of the present invention is to provide an arachidonic acid metabolism inhibitor that can be easily mass-produced.
本発明は、デカン酸、５−デセン酸、６−デセン酸から選ばれる少なくとも１つを有効成分として含有するアラキドン酸代謝抑制剤である。また、本発明はさらに、該アラキドン酸代謝抑制剤を有効成分とする、血流改善剤、抗血栓剤、抗炎症剤または抗アレルギー剤である。 The present invention is an arachidonic acid metabolism inhibitor containing as an active ingredient at least one selected from decanoic acid, 5-decenoic acid, and 6-decenoic acid. The present invention is further a blood flow improving agent, antithrombotic agent, anti-inflammatory agent or antiallergic agent comprising the arachidonic acid metabolism inhibitor as an active ingredient.
本発明によれば、アラキドン酸の代謝異常を改善し、血流促進、血栓予防、各種炎症およびアレルギー症状の予防、緩和の効果を得ることができる。 ADVANTAGE OF THE INVENTION According to this invention, the metabolic disorder of arachidonic acid can be improved and the effect of blood-flow promotion, thrombus prevention, prevention of various inflammations, and allergic symptoms, and an alleviation effect can be acquired.
本発明のデカン酸、５−デセン酸および６−デセン酸は、一般に香料として市販されており容易に入手することができる。また、いずれも公知の方法で製造することができる。たとえば、５（または６）−デセン酸は、特開昭５９−１１６２４７号公報、特開昭５８−０５９９０８号公報に記載の方法などにより製造することができる。 The decanoic acid, 5-decenoic acid and 6-decenoic acid of this invention are generally marketed as a fragrance | flavor, and can be obtained easily. Moreover, all can be manufactured by a well-known method. For example, 5 (or 6) -decenoic acid can be produced by the method described in JP-A-59-116247 and JP-A-58-059908.
本発明のアラキドン酸代謝抑制剤は、前記化合物をそれぞれ単独で用いてもよく、２種以上を配合して用いてもよい。 In the arachidonic acid metabolism inhibitor of the present invention, the above compounds may be used alone or in combination of two or more.
本発明のアラキドン酸代謝抑制剤は、用途に応じて、エタノール、水、プロピレングリコール、グリセリン、食用油脂またはそれらの混合溶液などの溶剤、医薬や食品に適用可能な塩類、糖、糖アルコール、賦形剤、可溶化剤、乳化剤、分散剤、安定化剤、抗酸化剤、色素、香料などを適宜配合することができる。 The arachidonic acid metabolism inhibitor of the present invention is a solvent such as ethanol, water, propylene glycol, glycerin, edible fats and oils or a mixed solution thereof, salts applicable to pharmaceuticals and foods, sugars, sugar alcohols, enhancers, depending on applications. Shapes, solubilizers, emulsifiers, dispersants, stabilizers, antioxidants, pigments, fragrances and the like can be appropriately blended.
本発明のアラキドン酸代謝抑制剤において、前記の化合物群の含有量は特に限定されないが、０．０００１〜１００質量％であることが好ましい。 In the arachidonic acid metabolism inhibitor of the present invention, the content of the compound group is not particularly limited, but is preferably 0.0001 to 100% by mass.
本発明のアラキドン酸代謝抑制剤の形態は、特に限定されない。例えば、液状のままでもよく、公知の方法によって乳化、分散、粉末化するなど、用途に応じて適宜選択することができる。 The form of the arachidonic acid metabolism inhibitor of the present invention is not particularly limited. For example, it may remain in a liquid state, and can be appropriately selected depending on the application, such as emulsification, dispersion, and powderization by a known method.
本発明のアラキドン酸代謝抑制剤は、ビタミン、ミネラル、アミノ酸、などの栄養強化剤、抗酸化剤、抗菌剤、その他の薬剤などと配合して使用することができる。また、本発明のアラキドン酸代謝抑制剤は、他のアラキドン酸代謝抑制剤と併用してもよい。 The arachidonic acid metabolism inhibitor of the present invention can be used in combination with nutrition enhancing agents such as vitamins, minerals and amino acids, antioxidants, antibacterial agents and other agents. The arachidonic acid metabolism inhibitor of the present invention may be used in combination with other arachidonic acid metabolism inhibitors.
本発明のアラキドン酸代謝抑制剤を、医薬品もしくは医薬部外品として製剤化する場合は、必要に応じて安定化剤、着色剤、嬌味剤、香料、賦形剤、溶剤、界面活性剤、乳化剤、保存剤、溶解補助剤、等張化剤、緩衝剤、保湿剤、結合剤、被覆剤、潤沢剤、崩壊剤、経皮吸収剤などを加え、液剤、粉剤、散剤、顆粒剤、錠剤、糖衣剤、カプセル剤、懸濁剤、座剤、浴剤、軟膏、クリーム、ゲル、貼付剤、注射液、点眼剤など任意の剤形を選択することができるが、本発明のアラキドン酸代謝抑制剤は、その緩和な作用から健康補助の目的に特に適していることから、特に経口摂取に適した剤形が好ましい。 When formulating the arachidonic acid metabolism inhibitor of the present invention as a pharmaceutical or quasi-drug, a stabilizer, a coloring agent, a flavoring agent, a fragrance, an excipient, a solvent, a surfactant, Add emulsifiers, preservatives, solubilizers, isotonic agents, buffers, humectants, binders, coatings, lubricants, disintegrants, transdermal agents, etc., liquids, powders, powders, granules, tablets , Sugar coatings, capsules, suspensions, suppositories, baths, ointments, creams, gels, patches, injections, eye drops, and the like, but the arachidonic acid metabolism of the present invention can be selected. Since the inhibitor is particularly suitable for the purpose of health support due to its mild action, a dosage form particularly suitable for oral intake is preferred.
本発明のアラキドン酸代謝抑制剤に用いる有効成分は、その多くが従来から主に香料として使用されている化合物であるため、飲食品や香粧品などに添加することができる。例えば、乳飲料、清涼飲料、嗜好飲料、アルコール飲料などの飲料、チョコレート、キャンディ、錠菓、ガム、スナック菓子、クッキー、ケーキ、その他焼き菓子などの菓子類、氷菓、アイスクリームなどの冷菓類、即席麺類、レトルト食品、冷凍食品などの調理食品、調味料、栄養補助食品などの食品類に添加することで、血流促進、血栓予防、炎症の緩和、アレルギー症状の低減など健康維持の機能を付加することができる。 Since many of the active ingredients used in the arachidonic acid metabolism inhibitor of the present invention are compounds that have been used mainly as fragrances, they can be added to foods and drinks, cosmetics, and the like. For example, beverages such as milk beverages, soft drinks, taste beverages, alcoholic beverages, chocolate, candy, tablet confectionery, gum, snack confectionery, cookies, cakes, other confectionery such as baked confectionery, frozen confectionery such as ice confectionery and ice cream, instant Add to foods such as noodles, retort foods, frozen foods, seasonings, dietary supplements and other foods to add health maintenance functions such as promoting blood flow, preventing blood clots, reducing inflammation, and reducing allergic symptoms can do.
前記飲食品には、血流改善および／または抗炎症効果を有する旨の表示を付すことができる。本発明における表示の具体的な態様としては、飲食品の包装、容器、店頭表示媒体、広告媒体などが挙げられる。 The food / beverage product can be marked with a blood flow improvement and / or an anti-inflammatory effect. Specific embodiments of the display in the present invention include food and beverage packaging, containers, storefront display media, advertising media, and the like.
本発明のアラキドン酸代謝抑制剤を飲食品に添加する場合、特に添加量の制限はないが、０．００１〜５質量％であることが好ましい。 When adding the arachidonic acid metabolism inhibitor of this invention to food-drinks, there is no restriction | limiting of the addition amount in particular, However, It is preferable that it is 0.001-5 mass%.
本発明のアラキドン酸代謝抑制剤を飲食品に添加する方法は、特に制限はないが必要に応じて、乳化剤、分散剤、安定化剤などを加えることもできる。 The method for adding the arachidonic acid metabolism inhibitor of the present invention to a food or drink is not particularly limited, but an emulsifier, a dispersant, a stabilizer and the like can be added as necessary.
本発明のアラキドン酸代謝抑制剤を飲食品に添加する場合は、ビタミン、ミネラル、アミノ酸などの栄養強化剤、抗酸化剤、抗菌剤、食物繊維、アラキドン酸代謝抑制以外による血流促進剤、抗血栓剤、抗アレルギー剤など他の機能性成分を本発明のアラキドン酸代謝抑制剤の機能を阻害しない範囲で併用することもできる。 When the arachidonic acid metabolism inhibitor of the present invention is added to foods and drinks, nutrition enhancers such as vitamins, minerals, amino acids, antioxidants, antibacterial agents, dietary fiber, blood flow promoters other than arachidonic acid metabolism inhibitors, Other functional components such as thrombotic agents and antiallergic agents can be used in combination as long as they do not inhibit the function of the arachidonic acid metabolism inhibitor of the present invention.
本発明のアラキドン酸代謝抑制剤は、香水、化粧水、ファンデーション、口紅、クリーム、ローション、乳液、ジェル、パック、日焼け止め、サンオイルなどの化粧品類、石鹸、ボディーシャンプー、洗顔料などの身体洗浄剤、シャンプー、リンス、ヘアートリートメント剤、整髪料、染毛剤、パーマネント剤、養毛剤などの毛髪化粧料、シェービングフォーム、シェービングクリーム、アフターシェーブローション、歯磨き、洗口剤、粉末洗剤、液体洗剤、漂白剤、柔軟剤、浴剤、衛生用品、避妊具などの香粧品類に添加することができる。 The arachidonic acid metabolism inhibitor of the present invention is a body wash such as perfumes, lotions, foundations, lipsticks, creams, lotions, emulsions, gels, packs, sunscreens, sun oils, soaps, body shampoos, face wash Agent, shampoo, rinse, hair treatment agent, hair conditioner, hair dye, permanent agent, hair cosmetics such as hair nourishing agent, shaving foam, shaving cream, after shave lotion, toothpaste, mouthwash, powder detergent, liquid detergent, bleaching agent It can be added to cosmetics such as softeners, bath preparations, hygiene products, and contraceptives.
また、接触性皮膚炎や、アレルギー症状を緩和する目的で、染料、顔料、塗料、ゴム、プラスチック、シリコン製品、紙製品、不繊布、繊維製品、コンクリート、フィルム、つや出し剤、接着剤、金属表面や木材表面などに付与するコーティング剤など、皮膚に接触する製品に添加することもできる。 Also, for the purpose of alleviating contact dermatitis and allergic symptoms, dyes, pigments, paints, rubber, plastics, silicon products, paper products, non-woven fabrics, textile products, concrete, films, polishes, adhesives, metal surfaces It can also be added to products that come into contact with the skin, such as coating agents applied to wood surfaces and the like.
本発明のアラキドン酸代謝抑制剤を香粧品類に添加する場合、特に添加量の制限はないが、０．００１〜１５質量％であることが好ましい。 When adding the arachidonic acid metabolism inhibitor of this invention to cosmetics, there is no restriction | limiting in particular in addition amount, However, It is preferable that it is 0.001-15 mass%.
本発明のアラキドン酸代謝抑制剤を香粧品に添加する方法は特に限定されないが、必要に応じて乳化剤、分散剤、安定化剤、賦形剤などを加えることもできる。 The method for adding the arachidonic acid metabolism inhibitor of the present invention to cosmetics is not particularly limited, but emulsifiers, dispersants, stabilizers, excipients and the like may be added as necessary.
本発明のアラキドン酸代謝抑制剤を香粧品に添加する場合は、抗酸化剤、ビタミン、ミネラル、アミノ酸、保湿剤、紫外線吸収剤、抗菌剤、抗かび剤、メラニン生成抑制剤、養毛剤、冷感剤、温感剤、吸収促進剤、アラキドン酸代謝抑制以外による血流促進剤、抗血栓剤、抗アレルギー剤など他の機能性物質を本発明のアラキドン酸代謝抑制剤の機能を阻害しない範囲で併用することもできる。 When adding the arachidonic acid metabolism inhibitor of the present invention to cosmetics, antioxidants, vitamins, minerals, amino acids, moisturizers, ultraviolet absorbers, antibacterial agents, antifungal agents, melanin production inhibitors, hair nourishing agents, cooling sensations Other functional substances such as blood flow promoters, antithrombotic agents, and antiallergic agents other than drugs, warming agents, absorption promoters, and arachidonic acid metabolism inhibitors, as long as the functions of the arachidonic acid metabolism inhibitor of the present invention are not inhibited. It can also be used together.
（試験方法）
人の血液に１０％濃度になるように３．８％クエン酸ナトリウム液を加え、この血液を１０００ｒｐｍで１０分間遠心分離し、上層部を採取、これを多血小板血漿（ＰＲＰ）とした。更に下層部を３０００ｒｐｍで１５分間遠心分離し、上層部より乏血小板血漿（ＰＰＰ）を採取して、これを血小板凝集能測定時におけるコントロールとした。
(Test method)
A 3.8% sodium citrate solution was added to human blood to a concentration of 10%, the blood was centrifuged at 1000 rpm for 10 minutes, and the upper layer was collected, and this was used as platelet-rich plasma (PRP). Further, the lower layer portion was centrifuged at 3000 rpm for 15 minutes, and platelet poor plasma (PPP) was collected from the upper layer portion, which was used as a control when measuring the platelet aggregation ability.
測定装置として、興和株式会社製の血小板凝集能測定装置（コーワＰＡ−２０）を使用し、被験物質を加えず、凝集惹起剤のみを加えた対象凝集曲線に対する最大凝集率を１００％とした時の各試料濃度段階の最大凝集率を求めた。 When a platelet aggregation measuring device (Kowa PA-20) manufactured by Kowa Co., Ltd. is used as the measuring device, the maximum aggregation rate with respect to the target aggregation curve without adding the test substance and adding only the aggregation-inducing agent is 100%. The maximum aggregation rate at each sample concentration step was determined.
被験物質を測定容器に入れ、さらにＰＲＰ２７０μｌを加えたものを測定装置に設置し、３７℃で撹拌しながら３０秒間インキュベートした。続いて、３０秒以内に凝集惹起剤として０．２Ｍに調整したアラキドン酸のメタノール溶液を２μＬ加え、測定容器設置から７分後までの凝集率を測定した。 A test substance was placed in a measurement container, and further 270 μl of PRP was added to the measurement apparatus and incubated at 37 ° C. with stirring for 30 seconds. Subsequently, 2 μL of a methanol solution of arachidonic acid adjusted to 0.2 M was added as an agglutination-inducing agent within 30 seconds, and the agglomeration rate was measured after 7 minutes from the installation of the measurement container.
アラキドン酸代謝阻害活性は、以下の計算方法により血小板凝集阻害率を求めることで評価した。
（血小板凝集阻害率計算法）
ＰＲＰ＋凝集惹起剤のみを加えたときの最大凝集率をＡとする。
被験物質＋ＰＲＰ＋アラキドン酸を加えたときの最大凝集率をＢとする。
凝集阻害率（％）をＣとすると
Ｃ＝１００−Ｂ／Ａ×１００
Arachidonic acid metabolism inhibitory activity was evaluated by determining the platelet aggregation inhibition rate by the following calculation method.
(Platelet aggregation inhibition rate calculation method)
A is the maximum aggregation rate when only PRP + aggregation inducing agent is added.
Let B be the maximum aggregation rate when test substance + PRP + arachidonic acid is added.
When the aggregation inhibition rate (%) is C, C = 100−B / A × 100
（試験結果）
前記試験方法において、被験物質１００μｇを添加した条件下で血小板凝集阻害活性を測定した。さらに活性が比較的高いものについて、被験物質５０μｇ、１０μｇを添加した条件下での血小板凝集阻害活性を測定した。
(Test results)
In the test method, the platelet aggregation inhibitory activity was measured under the condition where 100 μg of the test substance was added. Furthermore, about the thing with comparatively high activity, the platelet aggregation inhibitory activity on the conditions which added 50 micrograms of test substances and 10 micrograms was measured.
本発明のアラキドン酸代謝抑制剤の試験結果を、従来血小板凝集阻害活性が知られている市販のトウガラシチンキと、血流改善効果が知られている松樹皮抽出物を比較例として、表１に示す。 The test results of the arachidonic acid metabolism inhibitor of the present invention are shown in Table 1 as a comparative example using a commercially available chili tincture with a known platelet aggregation inhibitory activity and a pine bark extract with a known blood flow improving effect. Show.
表１に示すように本発明のアラキドン酸代謝抑制剤には、トウガラシチンキや松樹皮抽出物と比較して、同等かそれ以上の活性が確認された。 As shown in Table 1, the arachidonic acid metabolism inhibitor of the present invention was confirmed to have an activity equal to or higher than that of chili pepper or pine bark extract.
以下に本発明のアラキドン酸代謝抑制剤の製剤例について、一例を示す。 An example of a preparation example of the arachidonic acid metabolism inhibitor of the present invention is shown below.
錠剤配合例（質量比）
──────────────────────
本発明のアラキドン酸代謝抑制剤 ５．０
６％ＨＰＣ乳糖 ８０．０
ステアリン酸マグネシウム ４．０
バレイショデンプン ６．０
──────────────────────
Tablet formulation example (mass ratio)
──────────────────────
Arachidonic acid metabolism inhibitor of the present invention 5.0
6% HPC lactose 80.0
Magnesium stearate 4.0
Potato starch 6.0
──────────────────────
軟膏剤配合例（質量比）
─────────────────────────
白色ワセリン ２０．０
ステアリルアルコール ２２．０
プロピレングリコール １２．０
ラウリル硫酸ナトリウム １．５
パラベン ０．２
本発明のアラキドン酸代謝抑制剤 ５．０
精製水 ３９．３
─────────────────────────
Ointment formulation example (mass ratio)
─────────────────────────
White petrolatum 20.0
Stearyl alcohol 22.0
Propylene glycol 12.0
Sodium lauryl sulfate 1.5
Paraben 0.2
Arachidonic acid metabolism inhibitor of the present invention 5.0
Purified water 39.3
─────────────────────────
以下に本発明のアラキドン酸代謝抑制剤の食品への配合例について一例を示す。 An example of the formulation of the arachidonic acid metabolism inhibitor of the present invention in a food is shown below.
アイスクリーム配合例（質量比）
────────────────────────
全脂練乳 １０．０
生クリーム ９．４
無塩バター ２．０
脱脂粉乳 ３．４
砂糖 １２．０
安定剤 ０．３
乳化剤 ０．２
ｐＨ調整剤 ０．１
カラメル色素 ０．１
５−デセン酸、６−デセン酸混合物 ０．０１
香料 ０．０１
水 ４９．０
────────────────────────
Ice cream formulation example (mass ratio)
────────────────────────
Whole fat condensed milk 10.0
Fresh cream 9.4
Unsalted butter 2.0
Nonfat dry milk 3.4
Sugar 12.0
Stabilizer 0.3
Emulsifier 0.2
pH adjuster 0.1
Caramel pigment 0.1
5-decenoic acid, 6-decenoic acid mixture 0.01
Fragrance 0.01
Water 49.0
────────────────────────
クッキー生地配合例（質量比）
────────────────────────
薄力粉 ６２．５
全粒粉 ３７．５
ショートニング ３０．０
全卵 ３０．０
砂糖 ２０．０
水飴 １．０
脱脂粉乳 ５．０
食塩 １．２
食用油脂 ３０．０
重炭酸ソーダ １．０
重炭酸アンモニウム １．０
５−デセン酸、６−デセン酸混合物 ０．０１
イソブチルアンゲレート ０．００１
香料 ０．３
水 １１．０
────────────────────────
Cookie dough formulation example (mass ratio)
────────────────────────
Soft flour 62.5
Whole grain 37.5
Shortening 30.0
Whole egg 30.0
Sugar 20.0
Minamata 1.0
Nonfat dry milk 5.0
Salt 1.2
Edible oils and fats 30.0
Sodium bicarbonate 1.0
Ammonium bicarbonate 1.0
5-decenoic acid, 6-decenoic acid mixture 0.01
Isobutyl angelate 0.001
Fragrance 0.3
Water 11.0
────────────────────────
チョコレート配合例（質量比）
─────────────────────────
カカオ液 １２．０
カカオバター ２４．０
ショ糖 ３３．０
フルクリームミルクパウダー １９．０
スキムミルクパウダー １１．４
レシチン ０．５
５−デセン酸、６−デセン酸混合物 ０．０１
香料 ０．１
─────────────────────────
Chocolate formulation example (mass ratio)
─────────────────────────
Cocoa liquor 12.0
Cocoa butter 24.0
Sucrose 33.0
Full cream milk powder 19.0
Skim milk powder 11.4
Lecithin 0.5
5-decenoic acid, 6-decenoic acid mixture 0.01
Fragrance 0.1
─────────────────────────
本発明のアラキドン酸代謝抑制剤は、香料として使用実績がある化合物であり、刺激性などは極めて小さく、飲食品や香粧品類など幅広く添加することができる。また、本発明の化合物群は容易に合成ができるため、大量生産が可能である。 The arachidonic acid metabolism inhibitor of the present invention is a compound that has been used as a fragrance and has very little irritation and can be widely added to foods and drinks and cosmetics. In addition, since the compound group of the present invention can be easily synthesized, mass production is possible.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010264285A JP5305419B2 (en) | 2004-03-30 | 2010-11-26 | Platelet aggregation inhibitor |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004100586 | 2004-03-30 | ||
| JP2004100586 | 2004-03-30 | ||
| JP2005005240 | 2005-01-12 | ||
| JP2005005240 | 2005-01-12 | ||
| JP2010264285A JP5305419B2 (en) | 2004-03-30 | 2010-11-26 | Platelet aggregation inhibitor |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005097031A Division JP4657778B2 (en) | 2004-03-30 | 2005-03-30 | Arachidonic acid metabolism inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011037906A true JP2011037906A (en) | 2011-02-24 |
| JP5305419B2 JP5305419B2 (en) | 2013-10-02 |
Family
ID=43766012
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010264285A Expired - Fee Related JP5305419B2 (en) | 2004-03-30 | 2010-11-26 | Platelet aggregation inhibitor |
| JP2010264286A Pending JP2011037907A (en) | 2004-03-30 | 2010-11-26 | Arachidonic acid metabolism inhibitor |
| JP2010264284A Expired - Fee Related JP5305418B2 (en) | 2004-03-30 | 2010-11-26 | Platelet aggregation inhibitor |
| JP2013103610A Expired - Fee Related JP5582593B2 (en) | 2004-03-30 | 2013-05-16 | Platelet aggregation inhibitor |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010264286A Pending JP2011037907A (en) | 2004-03-30 | 2010-11-26 | Arachidonic acid metabolism inhibitor |
| JP2010264284A Expired - Fee Related JP5305418B2 (en) | 2004-03-30 | 2010-11-26 | Platelet aggregation inhibitor |
| JP2013103610A Expired - Fee Related JP5582593B2 (en) | 2004-03-30 | 2013-05-16 | Platelet aggregation inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (4) | JP5305419B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5911549B1 (en) * | 2014-10-27 | 2016-04-27 | 小川香料株式会社 | Taste improving agent for high-intensity sweeteners using salamander extract |
| JP6281926B1 (en) * | 2017-05-18 | 2018-02-21 | 長岡香料株式会社 | Taste improver for high-intensity sweeteners |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998035665A1 (en) * | 1997-02-14 | 1998-08-20 | Ajinomoto Co., Inc. | Counteractive for endotoxin |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US118714A (en) * | 1871-09-05 | Improvement in medical compounds | ||
| US238581A (en) * | 1881-03-08 | Bitters | ||
| JPH11318387A (en) * | 1989-10-31 | 1999-11-24 | Kanebo Ltd | Food product for anti-inflammation |
| JP3178822B2 (en) * | 1990-01-09 | 2001-06-25 | 鐘紡株式会社 | 3α-hydroxysteroid dehydrogenase inhibitory activator and hyaluronidase inhibitory activator |
| JP2002249435A (en) * | 2001-02-21 | 2002-09-06 | Spirulina Biological Lab Ltd | Composition and patch for facilitating blood circulation |
| JP4542300B2 (en) * | 2002-02-15 | 2010-09-08 | 株式会社ファンケル | Hyaluronic acid accumulation promoter |
| WO2004045632A1 (en) * | 2002-11-12 | 2004-06-03 | Kaneka Corporation | Peroxisome proliferator-activated recetor ligand |
| JP4875298B2 (en) * | 2004-12-28 | 2012-02-15 | 一丸ファルコス株式会社 | Trypsin inhibitor |
-
2010
- 2010-11-26 JP JP2010264285A patent/JP5305419B2/en not_active Expired - Fee Related
- 2010-11-26 JP JP2010264286A patent/JP2011037907A/en active Pending
- 2010-11-26 JP JP2010264284A patent/JP5305418B2/en not_active Expired - Fee Related
-
2013
- 2013-05-16 JP JP2013103610A patent/JP5582593B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998035665A1 (en) * | 1997-02-14 | 1998-08-20 | Ajinomoto Co., Inc. | Counteractive for endotoxin |
Non-Patent Citations (1)
| Title |
|---|
| JPN6010054968; Ｇｅｎ． Ｐｈａｒｍａｃ． ２２（４）, 1991, ｐｐ．７４１-７４８ * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5582593B2 (en) | 2014-09-03 |
| JP2011037907A (en) | 2011-02-24 |
| JP2011037905A (en) | 2011-02-24 |
| JP5305418B2 (en) | 2013-10-02 |
| JP5305419B2 (en) | 2013-10-02 |
| JP2013151575A (en) | 2013-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5224234B2 (en) | Platelet aggregation inhibitor | |
| JP2004026719A (en) | Antiobestic composition comprising extract of astringent coat of peanut as active ingredient | |
| JP5305419B2 (en) | Platelet aggregation inhibitor | |
| US11306117B2 (en) | Whitening composition containing novel quercetin-based compound | |
| JP5224235B2 (en) | Calcium antagonist | |
| JP4657778B2 (en) | Arachidonic acid metabolism inhibitor | |
| JP4953627B2 (en) | Arachidonic acid metabolism inhibitor | |
| JP2008013486A (en) | Arachidonate metabolism inhibitor | |
| JP5536913B2 (en) | Platelet aggregation inhibitor | |
| JP4906282B2 (en) | Melanin production inhibitor | |
| JP6456032B2 (en) | Sirt1 activator and use of the Sirt1 activator | |
| JP7179025B2 (en) | Anti-inflammatory composition containing novel kaempferol compounds derived from post-fermented tea | |
| JP5527736B2 (en) | Platelet aggregation inhibitor | |
| JP2013082738A (en) | Platelet aggregation inhibitor | |
| JP5626609B2 (en) | Calcium antagonist | |
| JP5536912B2 (en) | Platelet aggregation inhibitor | |
| JP7071406B2 (en) | Anti-inflammatory composition containing a novel quercetin compound | |
| JP7030692B2 (en) | Moisturizing composition containing 3-O-galloyl-3,3', 5,5', 7-pentahydroxyflavon | |
| JP2013082739A (en) | Platelet aggregation inhibitor | |
| JP5507892B2 (en) | Active oxygen-induced disorder inhibitor | |
| JP2013075914A (en) | Calcium antagonist | |
| JP6753662B2 (en) | Anti-glycation agent | |
| JP2023074268A (en) | IL-1α expression inhibitor | |
| JP2023059099A (en) | myonectin production promoter | |
| JP2023161718A (en) | PDE4 inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130404 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130530 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130620 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130620 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5305419 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |